SCHEMBL24744892

SCHEMBL24744892

Cc1ccc(C(=O)O)c2nc(C)n(CC(=O)OC(C)(C)C)c12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.39
ALDH1A1 P00352 2/20 0.39
CACNA1B Q00975 1/20 0.35
PLA2G7 Q13093 1/20 0.34
KMT2A Q03164 3/20 0.33
JAK2 O60674 1/20 0.33
JAK1 P23458 1/20 0.33
JAK3 P52333 1/20 0.33
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
PTGER4 P35408 1/20 0.32
HDAC6 Q9UBN7 2/20 0.31
F2 P00734 1/20 0.31
HSD17B10 Q99714 2/20 0.30
TLR7 Q9NYK1 1/20 0.30
MEN1 O00255 1/20 0.30
USP2 O75604 1/20 0.30
HPGD P15428 1/20 0.30
NPSR1 Q6W5P4 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24744879 0.89 KDM4E (0.38) KDM4EALDH1A1CACNA1BPLA2G7KMT2A
SCHEMBL31090637 0.88 KDM4E (0.37) KDM4EALDH1A1CACNA1BKMT2AJAK2
SCHEMBL30938924 0.88 KDM4E (0.37) KDM4EALDH1A1CACNA1BPLA2G7KMT2A
SCHEMBL24745424 0.88 KDM4E (0.37) KDM4EALDH1A1CACNA1BKMT2AJAK2
SCHEMBL31090538 0.88 KDM4E (0.37) KDM4EALDH1A1CACNA1BPLA2G7KMT2A
SCHEMBL24744893 0.88 KDM4E (0.37) KDM4EALDH1A1CACNA1BPLA2G7KMT2A
SCHEMBL31090615 0.87 JAK2 (0.39) KDM4EALDH1A1CACNA1BPLA2G7KMT2A
SCHEMBL24744853 0.87 JAK2 (0.39) KDM4EALDH1A1CACNA1BPLA2G7KMT2A
SCHEMBL24744761 0.81 KDM4E (0.46) KDM4EALDH1A1CACNA1BKMT2AHSD17B10
SCHEMBL30952847 0.81 KDM4E (0.46) KDM4EALDH1A1CACNA1BKMT2AHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240294499-A1 TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN CAPTOR THERAPEUTICS S.A. (PL) 2024-09-05 US disclosed
CN-117957218-A Targeted protein degradation using bifunctional compounds that bind to ubiquitin ligases and target MCL-1 proteins 凯普托尔治疗学股份有限公司 2024-04-30 CN disclosed
WO-2022253713-A1 TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN CAPTOR THERAPEUTICS S.A. (PL) 2022-12-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240294499-A1 TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN MCL1, MDM2, XIAP KDM4E 1943/4885ALDH1A1 956/4885CACNA1B 4588/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.